Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
1(10%)
Results Posted
80%(4 trials)

Phase Distribution

Ph phase_2
7
70%
Ph early_phase_1
1
10%
Ph phase_1
2
20%

Phase Distribution

3

Early Stage

7

Mid Stage

0

Late Stage

Phase Distribution10 total trials
Early Phase 1First-in-human
1(10.0%)
Phase 1Safety & dosage
2(20.0%)
Phase 2Efficacy & side effects
7(70.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

1

trials recruiting

Total Trials

10

all time

Status Distribution
Active(1)
Completed(5)
Terminated(1)
Other(3)

Detailed Status

Completed5
unknown3
Active, not recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
1
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (10.0%)
Phase 12 (20.0%)
Phase 27 (70.0%)

Trials by Status

completed550%
active_not_recruiting110%
withdrawn110%
unknown330%

Recent Activity

1 active trials
Showing 5 of 10
completedphase_2

N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma

NCT00253435
completedphase_1

MIBG With Dinutuximab +/- Vorinostat

NCT03332667
active_not_recruitingearly_phase_1

Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors

NCT03044977
unknownphase_2

A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects

NCT03561259
completedphase_2

131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat

NCT02035137
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT00253435Phase 2

N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma

Completed
NCT03332667Phase 1

MIBG With Dinutuximab +/- Vorinostat

Completed
NCT03044977Early Phase 1

Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors

Active Not Recruiting
NCT03561259Phase 2

A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects

Unknown
NCT02035137Phase 2

131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat

Completed
NCT03061656Phase 2

Tandem High Dose Chemotherapy With 131I-MIBG Treatment in High Risk Neuroblastoma

Unknown
NCT01413503Phase 2

A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors

Completed
NCT00028106Phase 2

131MIBG to Treat Malignant Pheochromocytoma

Completed
NCT01941849Phase 1

Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma

Withdrawn
NCT00013806Phase 2

CHP677: I-Metaiodobenzylguanidine (I-MIBG) Therapy for Refractory Neuroblastoma: a Phase II Study

Unknown

All 10 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
10